medigraphic.com

2018, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2018; 56 (3)

Treatment of hepatocarcinoma with celecoxib and pentoxifylline: a case report

Jiménez-Luévano MÁ, Rodríguez-Chávez JL, Ramírez-Flores S, Rodríguez-Villa P, Jiménez-Partida MÁ, Cervantes-Rodríguez G, Hernández-Flores G, Solís-Martínez R, Bravo-Cuellar A

Language: Spanish
References: 52
Page: 309-315
PDF size: 1149.95 Kb.


ABSTRACT

Background: Hepatocellular carcinoma (HCC) is the sixth most frequent tumor worldwide and it is responsible for approximately 750 000 deaths each year. It is the third leading cause of cancer death in Mexico. Despite the existing therapeutic regimens, HCC has a poor prognosis with a life expectancy of approximately one month in advanced cases. The use of celecoxib and pentoxifylline has recently been reported in tumor patients with promising results due to its anti-inflammatory, antiangiogenic, antifibrotic and proapoptotic effects. Nonetheless, the combination of both drugs for the treatment of HCC has never been employed.
Clinical case: 58-year-old male patient, who arrived to the examination room for presenting nausea, jaundice, asthenia, adynamia and encephalopathy grade I-II. The patient had a history of alcoholism for 47 years and diagnosis of cirrhosis in Child C stage. An image with focal lesion in the right lobe of 8 x 8 cm, which was highly vascularized, suggested HCC by means of imaging studies (ultrasound, computed axial tomography [CAT] and magnetic resonance imaging). Management began in January, 2015, and continues until today with 400 mg of pentoxifylline every 12 hours, 200 mg of celecoxib every 12 hours and vitamin supplements.
Conclusion: After one month, patient showed a surprising response, reduction in tumor size almost in its entirety, improvement of clinical condition, and turned into Child A stage. Eight months after treatment it was observed by CAT that the tumor had practically disappeared. Patient has survived for more than two years. These results are encouraging; however, it is necessary to conduct multicenter studies that prove the efficacy of the treatment.


REFERENCES

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar- Apr;61(2):69-90.

  2. Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current 2 status and future perspectives. World J Hepatol. 2015 Mar 27;7(3):406-24.

  3. López-Panqueva Rdel P. Neoplasias hepáticas malignas: 1.a parte. Hepatocarcinoma: papel de la biopsia hepática, estudios de inmunohistoquímica y otros aspectos importantes. Rev Col Gastroenterol. 2015;30(2):232-42.

  4. Aldaco-Sarvide F, Pérez-Pérez P, Cervantes-Sánchez G, TorrecillasTorres L, Erazo-V AE. Mortalidad por cáncer en México 2000-2010: el recuento de los daños. GAMO. 2012;11(6):371-9.

  5. Pin-Vieito N, Guerrero-Montañés A, Delgado-Blanco M. Hepatocarcinoma: estado actual. Galicia Clin. 2014;75(4):171-81.

  6. Cuevas-Avendaño A, Solís-y Solís V, Alonso-Patrón C, Méndez-Vivas WR. Hepatocarcinoma en hígado no cirrótico. Evid Med Invest Salud. 2015;8(1):32-6.

  7. Gonzalez-Huezo MS, Sánchez-Ávila JF. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Rev Gastroenterol Mex. 2014;79(4):250-62.

  8. Méndez-Sánchez N, Villa AR, Vázquez-Elizondo G, Ponciano-Rodríguez G, Uribe M. Mortality trends for liver cancer in Mexico from 2000 to 2006. Ann hepatol 2008;7(3):226-9.

  9. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology. 2008 May;134(6):1752-63.

  10. Erazo-Valle Solís AA, Escudero-de los Ríos PM, Arellano- Sotelo J, Barrera-Franco JL, Benítez-Arroyo H, Cabrera- Galeana PA et al. Guía mexicana de tratamiento del hepatocarcinoma avanzado. GAMO. 2012;11 Supl 2.

  11. Kim JU, Shariff MIF, Crossey MME, Gomez-Romero M, Holmes E, Cox IJ, et al. Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol. 2016 Apr 8; 8(10):471-84.

  12. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016 Apr;150(4):835-53.

  13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008;359:378-90.

  14. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002 Mar- Apr;9(2 Suppl):28-35.

  15. Chávez E, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Castro-Sánchez L, et al. Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. Liver Int. 2010 Aug;30(7):969-78.

  16. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002 Feb 1;62(3):625-31.

  17. Hernández LA, Cesin L, Fernández H. Efectos de la pentoxifilina en la formación de adherencias peritoneales postoperatorias en ratas. Rev Cient Cienc Med. 2016;19(1):5-11.

  18. Ye JH, Chao J, Chang ML, Peng WH, Cheng HY, Liao JW, et al. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid !-oxidation. Sci Rep. 2016;6:93102.

  19. Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology. 2012 Oct;56(4):1291-9.

  20. Ward A, Clissold S. Pentoxifylline. Review of its pharmacodynamic and pharmacokinetic properties. Drugs. 1987;34(1):50-97.

  21. Weber A, Boege Y, Reisinger F, Heikenwälder M. Chronic liver inflammation and hepatocellular carcinoma: persistence matters. Swiss Med Wkly. 2011 May 10;141:w13197.

  22. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinicohistopathologic study of 804 North American patients. Am J Clin Pathol. 1996 Jan;105(1):65-75.

  23. Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol. 2006;12(32):5113-21.

  24. Chen CC, Sun YT, Chen JJ, Chang YJ. Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via 4 sequential activation of ceramide-dependent mitogenactivated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol. 2001 Mar;59(3):493-500.

  25. Chen CC, Sun YT, Chen JJ, Chiu KT. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol. 2000 Sep 1;165(5):2719-28.

  26. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012 Mar;3(3):236-60.

  27. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, et al.; HALT-C Trial Group. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul;141(1):141-9.

  28. Liu Y, Liu A, Li H, Li C, Lin J. Celecoxib Inhibits Interleukin- 6/Interleukin-6 Receptor–Induced JAK2/STAT3 Phosphorylation in Human Hepatocellular Carcinoma Cells. Cancer Prev Res (Phila). 2011 Aug;4(8):1296-305.

  29. Zhang B, Zhong DW, Wang QW, Miao XY, Dai WD, Liu C, et al. [Study on correlation of JAK/STAT signal pathway with progression and prognosis in hepatocellular carcinoma] (English abstract; Lang Chi). Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010;26:368-70.

  30. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8:945-54.

  31. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol. 2008;19:353-8.

  32. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002;62:625-31.

  33. Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006 Jun 7;98(11):736-47.

  34. Cui J, Guo Y, Zhang H, Jiang L, Ma J, Wang W, et al. Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids. Onco Targets Ther. 2014;7:353-63.

  35. Ftahy MM, Abdl Latif NS, Alalkamy EF, El-Batrawi FA, Galal AH Khatab HM. Antifibrotic potential of a selective COX-2 inibithor (celecoxib) on liver fibrosis in rats. Comparative Clinical Pathology. 2012;22(3)425:30.

  36. Bassiouny AR, Zaky A, Neenaa HM. Synergistic effect of celecoxib on 5-fluoracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol. 2010 Oct-Dec;9(4):410-8.

  37. Kim JS, Park BR, Nam GH, Bae DH. Synergistic effects of sorafenib and celecoxib inhibit growth and VEGF expression in Hec-1A endometrial cancer cell line. Korean J Obstet Gynecol. 2012 Nov;55(11):814-21.

  38. Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, et al. Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro- Apoptotic Effects in Human Liver Cancer Cells. PLOS ONE. 2013;8(6):e65569.

  39. Ren F, Fan M, Mei J, Wu Y, Liu C, Pu Q, et al. Interferon-" and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. Drug Des Devel Ther. 2014 Sep 23;8:1527-38.

  40. Solís-Martínez R, Hernández-Flores G, Ortiz-Lazareno PC, Ochoa-Carrillo FJ, Bravo-Cuellar A. Macrófagos asociados a tumores contribuyen a la progresión del cáncer de próstata. GAMO. 2015;14(2):97-102.

  41. Jiménez-Luévano MA, Rodríguez-Villa P, Ramírez-Flores S, Jiménez-Partida M, Orozco-Chávez E, Aguilar- Rodríguez R et al. Efecto de la pentoxifilina en hepatitis colestásica aguda: reporte de dos casos. Rev Biomed. 2015;26:99-105.

  42. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol. 1997 Aug;29(2):181- 96.

  43. Genovés P, García D, Cejalvo D, Martin A, Zaragoza C, Toledo AH, et al. Pentoxifylline in liver ischemia and reperfusion. J Invest Surg. 2014 Apr;27(2):114-24.

  44. Smart L, Gobejishvili L, Crittenden N, Barve S, McClain CJ. Alcoholic Hepatitis: Steroids vs. Pentoxifylline. Curr Hepat Rep. 2013 Mar 1;12(1):59-65.

  45. Hammam O, Mahmoud O, Zahran M, Sayed A, Hosny K, Farghly A, et al. Tissue Expression of TNF a and VEGF in Chronic Liver Disease and Hepatocellular Carcinoma. Med J Cairo Univ. 2013 June; 81(2):191-9.

  46. Gonzalez GJ. Pentoxifilina: revisión de sus características farmacológicas y su utilización en la práctica clínica. Flebología y Linfología / Lecturas Vasculares. 2007;2(4):157-220.

  47. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.

  48. Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, et al. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in 6 vitro. Anticancer Res. 2013 Apr;33(4):1387-95.

  49. Guarneri A, Franco P, Trino E, Campion D, Faletti R, Mirabella S, et al. Stereotactic ablative radiotherapy in the treatment of hepatocellular carcinoma >3 cm. Med Oncol. 2016 Oct;33(10):104.

  50. Meza-Junco J, Montaño-Loza A, Green-Rener D. Utilidad de las clasificaciones clínicas en el pronóstico del carcinoma hepatocelular. Rev Gastroenterol Mex. 2006;71(2):160-8.

  51. Hernandez-Flores G, Ortiz-Lazareno PC, Lerma-Diaz JM, Dominguez-Rodriguez JR, Jave-Suarez LF, Aguilar- Lemarroy Adel C, et al. Pentoxifylline sensitizes human cervical tumor cells to cisplatin-induced apoptosis by suppressing NF-kappa B and decreased cell senescence. BMC Cancer. 2011 Nov 10;11:483.

  52. Gonzalez-Ramella O, Ortiz-Lazareno PC, Jiménez-López X, Gallegos-Castorena S, Hernández-Flores G, Medina- Barajas F, et al. Pentoxifylline during steroid window phase at induction to remission increases apoptosis in childhood with acute lymphoblastic leukemia. Clin Transl Oncol. 2016 Apr;18(4):369-74.




2020     |     www.medigraphic.com